Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is TATA Health International Holdings 3-Year ROIIC %?
TATA Health International HoldingsHKSE:01255 +0.24%22 3-Year ROIIC % is 1.35 as of Dec. 2025, which is 95% below its 10-year median of 27.51. GuruFocus rates HKSE:01255 with a GF Score™ of 22/100 and a GF Value™ of HK$0.21 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 1,019 Manufacturing - Apparel & Accessories companies, TATA Health International Holdings ranks worse than 50.64% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
TATA Health International Holdings's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 1.35%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
HKSE:01255's 3-Year ROIIC % is ranked worse than 50.64% of 1019
companies
in the Manufacturing - Apparel & Accessories industry
Industry Median: 1.53
vs HKSE:01255: 1.35
TATA Health International Holdings (HKSE:01255) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
TATA Health International Holdings 3-Year ROIIC % Related Terms
TATA Health International Holdings 3-Year ROIIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TATA Health International Holdings 3-Year ROIIC % Chart
HKSE:01255 vs NKE, DECK, ONON: 3-Year ROIIC % Comparison
For the Footwear & Accessories subindustry, TATA Health International Holdings's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TATA Health International Holdings 3-Year ROIIC % vs Manufacturing - Apparel & Accessories Industry
For the Manufacturing - Apparel & Accessories industry and Consumer Cyclical sector, TATA Health International Holdings's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where TATA Health International Holdings's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
TATA Health International Holdings (HKSE:01255) has a 3-Year ROIIC % of 1.35 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on TATA Health International Holdings and its competitors. This is 95% below median its historical median of 27.51. According to the industry distribution chart, TATA Health International Holdings ranks #516 out of 1019 companies in the Manufacturing - Apparel & Accessories industry, placing it in the top 50.6%.
Is TATA Health International Holdings' 3-Year ROIIC % too high?
TATA Health International Holdings' current 3-Year ROIIC % of 1.35 is 95% below median its 10-year median of 27.51. The Manufacturing - Apparel & Accessories industry median 3-Year ROIIC % is 1.53. TATA Health International Holdings' value of 1.35 is 11.8% below this industry median. Based on the distribution chart, TATA Health International Holdings ranks #516 out of 1019 companies in the Manufacturing - Apparel & Accessories industry, which is below the industry midpoint. Overall, TATA Health International Holdings has a GF Score™ of 22/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does TATA Health International Holdings' 3-Year ROIIC % compare to NKE and DECK?
According to the Manufacturing - Apparel & Accessories industry distribution chart, TATA Health International Holdings ranks #516 out of 1019 companies for 3-Year ROIIC %. This places TATA Health International Holdings in the lower half of its industry. The industry median 3-Year ROIIC % is 1.53. TATA Health International Holdings' value of 1.35 is 11.8% below this benchmark. While the company's 10-year median is 27.51 vs. the industry median of 1.53, TATA Health International Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Manufacturing - Apparel & Accessories company?
The median 3-Year ROIIC % among Manufacturing - Apparel & Accessories companies is 1.53, based on 1,019 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TATA Health International Holdings's current 3-Year ROIIC % of 1.35 is 11.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on TATA Health International Holdings and its competitors. For the Manufacturing - Apparel & Accessories industry, the median 3-Year ROIIC % is 1.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TATA Health International Holdings's current 3-Year ROIIC % is 1.35, which is 95% below median its own 10-year median of 27.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TATA Health International Holdings stock overvalued right now?
Based on GuruFocus' analysis, TATA Health International Holdings (HKSE:01255) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.21, compared to a current price of HK$2.10 — trading 900% above its estimated fair value. The current 3-Year ROIIC % is 1.35, which is 95% below median its 10-year median of 27.51 and 11.8% below the Manufacturing - Apparel & Accessories industry median of 1.53. TATA Health International Holdings' overall GF Score™ is 22/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For TATA Health International Holdings (HKSE:01255), the current 3-Year ROIIC % is 1.35 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TATA Health International Holdings (HKSE:01255) Overvalued in 2026?
Based on GuruFocus' analysis, TATA Health International Holdings stock appears to be overvalued.
The current stock price of HK$2.10 is trading 900% above its estimated GF Value™ of HK$0.21.
GuruFocus considers TATA Health International Holdings to be Significantly Overvalued.
Key valuation signals for HKSE:01255:
3-Year ROIIC %: 1.35 (95% below median its 10-year median of 27.51)
GF Value™: HK$0.21 vs. price of HK$2.10 (900% above fair value)
Industry Position: 11.8% below the Manufacturing - Apparel & Accessories median (#516 of 1019)
No single metric tells the full story. See the HKSE:01255 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TATA Health International Holdings Ltd is an investment holding company. Through its subsidiaries, the company operates in four segments: Trading of footwear products, Trading of healthcare products, Financial services, and Online medical services. The majority of its revenue comes from the Trading of footwear products. Geographically, the Group generates maximum revenue from Hong Kong, and the rest from Macau.
22GF Score
Get the complete analysis for HKSE:01255
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01255 has been successfully added to your 
